Literature DB >> 6752024

Stimulation of resistance of immunocompromised mice by a muramyl dipeptide analog.

Y Osada, M Mitsuyama, K Matsumoto, T Une, T Otani, H Ogawa, K Nomoto.   

Abstract

L18-MDP(Ala), a synthetic derivative of muramyl dipeptide, enhanced resistance against Escherichia coli and Candida albicans infections in aged mice and younger adult mice whose defense mechanism(s) had been depressed by X-ray irradiation or by treatment with cyclophosphamide.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6752024      PMCID： PMC347677          DOI： 10.1128/iai.37.3.1285-1288.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  17 in total

1.  Augmented resistance to Listeria monocytogenes in mice at an early stage of aging.

Authors:  T Matsumoto; S Miake; M Mitsuyama; K Takeya; K Nomoto
Journal:  J Clin Lab Immunol       Date:  1979-04

Review 2.  Lung damage from cytotoxic drugs.

Authors:  C H Collis
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

3.  Effects of muramyl dipeptide treatment on resistance to infection with Toxoplasma gondii in mice.

Authors:  J L Krahenbuhl; S D Sharma; R W Ferraresi; J S Remington
Journal:  Infect Immun       Date:  1981-02       Impact factor: 3.441

4.  Enhancement of host resistance against Trypanosoma cruzi infection by the immunoregulatory agent muramyl dipeptide.

Authors:  F Kireszenbaum; R W Ferraresi
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

5.  Infectious complications associated with hairy cell leukemia.

Authors:  H M Golomb; S B Hanauer
Journal:  J Infect Dis       Date:  1981-05       Impact factor: 5.226

6.  Enhancement of certain biological activities of muramyl dipeptide derivatives after conjugation to a multi-poly(DL-alanine)--poly(L-lysine) carrier.

Authors:  L Chedid; M Parant; F Parant; F Audibert; F Lefrancier; J Choay; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

7.  Failure of intensive combination therapy (cyclophosphamide, adriamycin, 5-fluorouracil) to control adenocarcinoma or large-cell anaplastic carcinoma of lung.

Authors:  R E Taylor; I E Smith; H T Ford; B M Bryant; A J Casey; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

8.  Activation of macrophages for enhanced release of superoxide anion and greater killing of Candida albicans by injection of muramyl dipeptide.

Authors:  N P Cummings; M J Pabst; R B Johnston
Journal:  J Exp Med       Date:  1980-12-01       Impact factor: 14.307

9.  Stimulation of nonspecific resistance to infection induced by 6-O-acyl muramyl dipeptide analogs in mice.

Authors:  K Matsumoto; H Ogawa; T Kusama; O Nagase; N Sawaki; M Inage; S Kusumoto; T Shiba; I Azuma
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

10.  The use of four-drug combination chemotherapy (D.A.V.E.) in the treatment of advanced Wilms' tumour.

Authors:  D B Dunger; J S Malpas; J R Graham-Pole; M R Sandland; A G Stansfeld; J E Freeman
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333
View more
  9 in total

1.  Synergistic induction of cytotoxicity in macrophages by murine interferon-gamma and biological response modifiers derived from microorganisms.

Authors:  S Nagao; K Sato; Y Osada
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

2.  Synergistic effects of romurtide and cefmenoxime against experimental Klebsiella pneumonia in mice.

Authors:  O Tatara; C Nakahama; Y Niki
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

3.  Enhanced antibacterial resistance in neutropenic mice treated with human recombinant interleukin-1 beta.

Authors:  R Gladue; A Girard; M Newborg
Journal:  Agents Actions       Date:  1988-06

4.  Stimulation of non-specific resistance to infections by synthetic immunoregulatory agents.

Authors:  M Parant; L Chedid
Journal:  Infection       Date:  1985       Impact factor: 3.553

5.  Enhancement of host resistance against Listeria infection by Lactobacillus casei: role of macrophages.

Authors:  K Sato
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

6.  Stimulation of non-specific resistance to infections by synthetic immunoregulatory agents.

Authors:  M Parant; L Chedid
Journal:  Infection       Date:  1984 May-Jun       Impact factor: 3.553

7.  Stimulation of complement production in mice by N alpha-(N-acetylmuramyl-L-alanyl-D-isoglutamine)-N epsilon-stearoyl-L-lysine.

Authors:  N Endo; T Okuda; Y Osada; H Zen-Yoji
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

8.  Stimulation of nonspecific resistance to infection induced by muramyl dipeptide analogs substituted in the gamma-carboxyl group and evaluation of N alpha-muramyl dipeptide-N epsilon-stearoyllysine.

Authors:  K Matsumoto; T Otani; T Une; Y Osada; H Ogawa; I Azuma
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.441

Review 9.  Translation of peptidoglycan metabolites into immunotherapeutics.

Authors:  Matthew E Griffin; Charles W Hespen; Yen-Chih Wang; Howard C Hang
Journal:  Clin Transl Immunology       Date:  2019-11-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.